We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+2.62%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$797M
AUM Growth
+$84.1M
Cap. Flow
+$99.1M
Cap. Flow %
12.43%
Top 10 Hldgs %
92.1%
Holding
17
New
3
Increased
5
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
VYNE icon
VYNE Therapeutics
VYNE
+$46M
2
GKOS icon
Glaukos
GKOS
+$12.4M
3
AKBA icon
Akebia Therapeutics
AKBA
+$12.2M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$11.1M
5
SPNE
SeaSpine Holdings Corporation Common Stock
SPNE
+$9.46M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$4.04M

Sector Composition

Rank Sector Weight
1 Healthcare 96.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$175M
$436M 54.68%
3,549,320
– –
XLRN
2
DELISTED
Acceleron Pharma
XLRN
$60.8M 7.62%
1,553,937
– –
VYNE icon
3
VYNE Therapeutics
VYNE
$19.1M
$51.2M 6.42%
+378
New +$46M
CRVS icon
4
Corvus Pharmaceuticals
CRVS
$1.08B
$51M 6.39%
4,420,516
+1,176,470
+36% +$11.1M
COGT icon
5
Cogent Biosciences
COGT
$6.76B
$31.7M 3.97%
+166,295
New +$7.39M
AKBA icon
6
Akebia Therapeutics
AKBA
$335M
$29.5M 3.7%
3,100,000
+875,000
+39% +$12.2M
MRUS
7
DELISTED
Merus
MRUS
$26.1M 3.28%
1,410,417
– –
GKOS icon
8
Glaukos
GKOS
$8.74B
$17.4M 2.19%
565,165
+408,736
+261% +$12.4M
DERM
9
DELISTED
Dermira, Inc.
DERM
$15.9M 2%
1,993,746
+9,382
+0.5% +$204K
VRNA
10
DELISTED
Verona Pharma
VRNA
$14.8M 1.86%
740,740
– –
NBRV
11
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$14.7M 1.84%
11,699
– –
CRSP icon
12
CRISPR Therapeutics
CRSP
$4.71B
$10.2M 1.28%
223,317
– –
KIDS icon
13
OrthoPediatrics
KIDS
$513M
$9.41M 1.18%
624,591
+245,577
+65% +$4.35M
SPNE
14
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$9.33M 1.17%
+920,380
New +$9.46M
RARX
15
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$7.78M 0.98%
1,465,838
-565,724
-28% -$4.04M
WMGIZ
16
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
IVTY
17
DELISTED
Invuity, Inc
IVTY
$5.25M 0.66%
1,363,848
– –

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q1 2018 Portfolio in Review

As of Q1 2018, Novo Holdings A/S held 17 positions worth $797M, up 12% from $713M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Novo Holdings A/S deployed $99.1M of net new capital in Q1 2018, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was VYNE Therapeutics: 378 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $4.04M trimmed.

  • Novo Holdings A/S's largest Q1 2018 buy was VYNE Therapeutics: 378 shares worth $51.2M.
  • Novo Holdings A/S added most to Glaukos in Q1 2018, an estimated $12.4M increase.
  • Novo Holdings A/S's biggest Q1 2018 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $4.04M.
  • Novo Holdings A/S's ten largest holdings make up 92% of its $797M portfolio in Q1 2018.
  • Novo Holdings A/S opened 3 new positions and closed 0 in Q1 2018.
  • Novo Holdings A/S's portfolio value rose 12% quarter-over-quarter to $797M.

Based on Novo Holdings A/S's 13F filing for Q1 2018, filed 15 May 2018.